

# Oral $\alpha_4\beta_7$ integrin inhibitor MORF-057 demonstrates exposure driven biomarker response in non-human primates

---

Jamie Wong PhD, Morpnic Therapeutic  
Waltham MA USA  
February 2022



# Disclosures of potential conflicts of interest:




- Jamie Wong is an employee and shareholder of Morphic Therapeutic.

# NHP as a model for demonstrating $\alpha_4\beta_7$ inhibition



- Inhibition of  $\alpha_4\beta_7$  is a clinically validated mechanism for IBD-- VARSITY Trial (Sands, NEJM 2019)
- NHP valuable model system for proof-of-mechanism studies (Fedyk, 2012)
- MORF-057 an oral, small molecule  $\alpha_4\beta_7$  inhibitor completed Ph1 demonstrating safety, PK, RO, and proof of biology (Ray, ECCO 2021)

# $\alpha_4\beta_7$ mRNA is expressed by several immune cell subtypes




- scRNAseq data from naïve NHP CD45<sup>+</sup> PBMCs, n=2

# Experimental design



- Naïve NHPs were dosed orally, twice daily (BID), with MORF-057 10-50 mg/kg; 5 studies, total n=40
- Duration of dosing: 2-7 days

## Daily measurements:

- Drug plasma concentration (LC-MS)
- Target engagement:  $\alpha_4\beta_7$  receptor occupancy (FACS)
- $\beta_7$ -high CD4<sup>+</sup> T memory cell frequency (FACS)
- Circulating CCR9 mRNA levels (bDNA)




# High receptor occupancy (RO) shown in all samples




- Receptor occupancy was greater than 95% for all MORF-057 exposures measured, including the lowest, 4.5 ng/ml

# T<sub>mem</sub> cell and CCR9 blood biomarkers increase with MORF-057 exposure



CD4<sup>+</sup> T memory cells defined by: CD45<sup>+</sup>CD3<sup>+</sup>CD20<sup>-</sup>CD4<sup>+</sup>CD8<sup>-</sup>CD45RA<sup>-</sup>



Circulating CCR9 mRNA levels were measured in comparison with housekeeping genes (ACTB, IPO8, B2M, TBP)

- β<sub>7</sub><sup>high</sup> CD4<sup>+</sup> T<sub>mem</sub> biomarker increases with plasma exposure and dosing correlated with elevated CCR9 transcript

# Conclusions

- Circulating  $\beta_7$ -high T memory cells are a sensitive biomarker, and demonstrated a dose-dependent response to MORF-057 exposure
- CCR9 mRNA levels also showed similar exposure related changes
- scRNAseq data shows expression of  $\alpha_4\beta_7$  on other cell types beyond T memory cells including:  $T_N$ ,  $T_{Reg}$ ,  $T_{Eff}$ , NK, NKT,  $B_N$ ,  $B_{Mem}$ , plasmablasts, monocytes, and eosinophils
- Pharmacodynamic changes in NHP are consistent with MORF-057 human Phase 1 data in healthy volunteers (Ray, ECCO 2021); Phase 2 initiation for UC anticipated 1Q2022

## Contributors:

Dooyoung Lee, Maloy Mangada, Vinod Yadav, Dawn Troast, Cheng Zhong, Kristopher Hahn, Wei Wang, Xiaomei Ge, Lili Sun, Shihao Jiang, Lichang Yan, Binbin Wang, Jinfeng Zhang, Liping Yan, Hanh Nguyen, Dan Cui, Matthew G. Bursavich, Blaise Lippa, Bruce N. Rogers, and Adrian S. Ray